Phase III trial to evaluate palbociclib (PD-0332991), a cyclin kinase 4/6 inhibitor, in patients with HR+/HER2 normal primary breast cancer and a high risk of relapse following neoadjuvant chemotherapy.
GBG Forschungs GmbH is conducting this trial in cooperation with the AGO-B, the Breast International Group (BIG) and the NSABP Foundation.
Detailed information about the trial is publicly accessible at Clinical Trials.gov u under NCT01864746:
Data on GBG study PenelopeB and several collaborative projects will be presented at the SABCS Virtual Meeting 2020.
GS1-02 Oral presentation Wednesday, December 9, 2020. General Session 1
Moderator: Angela DeMichele, MD, MSCE, Time: 8:15-8-30 AM CT
Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B
Loibl S, Marmé F, Martin M, et al.
Recruiting was closed at December 2017.
By way of background therapy, all patients will receive endocrine treatment in accordance with standard guidelines.
Primary trial objective: comparison of invasive-disease-free survival (IDFS)
Inclusion and ecxlusion criteria and detailed information about trial design can be found in the protocol summary in the document section.
Registered centres can access further documents in the password-protected section of this website for internal use.
Registered centres can access further documents in the password-protected section of this website for internal use. Please log in here.
Dr. Thomas Ballhausen
GBG Forschungs GmbH
Martin Behaim Strasse 12
Fon: +49 6102 7480-0
Fax: +49 6102 7480-440
Coordinating Investigator in Germany: Prof. Dr. Toralf Reimer
International Investigator: Prof. Dr. Gunter von Minckwitz